ProCE Banner Activity

Treating a Patient With Newly Diagnosed Metastatic Squamous NSCLC and Low PD-L1 Expression

Multimedia
Watch this on-demand video for expert perspective on how to apply the latest clinical data to treating patients with metastatic squamous NSCLC and low tumor PD-L1 expression.

Released: August 21, 2018

Share

Faculty

Heather J. Jackson

Heather J. Jackson, PhD, FNP-BC, NEA-BC, FAANP

Associate Professor
Division of Hematology/Oncology
Department of Medicine
Vanderbilt University School of Nursing
Administrative Director of Advanced Practice
Division of Hematology/Oncology
Department of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AstraZeneca

Bristol Myers Squibb

Celgene TEXT Only

Genentech TEXT Only

Lilly

Merck Oncology

Novartis Pharmaceuticals Corporation

Takeda Oncology

Learning Objectives

  • Plan individualized treatment strategies based on histology as well as patient age/fitness, comorbidities, and preferences

Faculty Disclosure

Primary Author

Heather J. Jackson, PhD, FNP-BC, NEA-BC, FAANP

Associate Professor
Division of Hematology/Oncology
Department of Medicine
Vanderbilt University School of Nursing
Administrative Director of Advanced Practice
Division of Hematology/Oncology
Department of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee

H. Jack West, MD, has disclosed that he has received consulting fees from Ariad, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech/Roche, Merck, and Takeda and fees for non-CME/CE services from Ariad, AstraZeneca, Lilly, and Takeda.

Staff Disclosure

Staff

Rachael M. Andrie, PhD

Clinical Editor

Rachael M. Andrie, PhD, has no real or apparent conflicts of interest to report.

Megan K. Murphy, PhD

Scientific Director

Megan K. Murphy, PhD, has no real or apparent conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.